Immune checkpoint inhibition, including PD‐1/PD‐L1 blockade, greatly improves the prognosis of patients with mRCC.[9] HIF has been shown to upregulate PD‐L1 on tumor cells; similarly, VEGF upregulates PD‐1 on immune cells, promoting T cell exhaustion in the RCC microenvironment.[10] Thus, patients with mRCC may benefit from the combination of TKIs with PD‐1/PD‐L1 blockade.[11] Recent findings from clinical trials suggest that the combination of TKIs with PD‐1/PD‐L1 inhibitors may improve the overall survival of patients with RCC.[10]. The gene discussed is VEGFA; the disease is neoplasm.